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Abstract
Background: The viral genome of HIV-1 contains several secondary structures that are important for regulating
viral replication. The stem-loop 1 (SL1) sequence in the 5′ untranslated region directs HIV-1 genomic RNA
dimerization and packaging into the virion. Without SL1, HIV-1 cannot replicate in human T cell lines. The
replication restriction phenotype in the SL1 deletion mutant appears to be multifactorial, with defects in viral RNA
dimerization and packaging in producer cells as well as in reverse transcription of the viral RNA in infected cells. In
this study, we sought to characterize SL1 mutant replication restrictions and provide insights into the underlying
mechanisms of compensation in revertants.
Results: HIV-1 lacking SL1 (NLΔSL1) did not replicate in PM-1 cells until two independent non-synonymous
mutations emerged: G913A in the matrix domain (E42K) on day 18 postinfection and C1907T in the SP1 domain
(P10L) on day 11 postinfection. NLΔSL1 revertants carrying either compensatory mutation showed enhanced
infectivity in PM-1 cells. The SL1 revertants produced significantly more infectious particles per nanogram of p24
than did NLΔSL1. The SL1 deletion mutant packaged less HIV-1 genomic RNA and more cellular RNA, particularly
signal recognition particle RNA, in the virion than the wild-type. NLΔSL1 also packaged 3- to 4-fold more spliced
HIV mRNA into the virion, potentially interfering with infectious virus production. In contrast, both revertants
encapsidated 2.5- to 5-fold less of these HIV-1 mRNA species. Quantitative RT-PCR analysis of RNA cross-linked with
Gag in formaldehyde-fixed cells demonstrated that the compensatory mutations reduced the association between
Gag and spliced HIV-1 RNA, thereby effectively preventing these RNAs from being packaged into the virion. The
reduction of spliced viral RNA in the virion may have a major role in facilitating infectious virus production, thus
restoring the infectivity of NLΔSL1.
Conclusions: HIV-1 evolved to overcome a deletion in SL1 and restored infectivity by acquiring compensatory
mutations in the N-terminal matrix or SP1 domain of Gag. These data shed light on the functions of the N-terminal
matrix and SP1 domains and suggest that both regions may have a role in Gag interactions with spliced viral RNA.
Background
HIV-1 packages two copies of the viral RNA genome, in
dimeric form, through Gag-RNA interactions [1-5]. The
cis-acting elements in the viral RNA and Gag are
involved in the specific packaging of HIV-1 genomic
RNA. The 5′ noncoding leader sequence of the HIV-1
genome contains important cis-acting packaging ele-
ments. This leader region forms a series of secondary
structures, including the transactivation response ele-
ment, the poly(A) hairpin, the U5-PBS complex, and
stem loops (SL) 1 to 4 [6-8]. Despite some sequence
variations, different subtypes of HIV-1 all have similar
secondary structures in this region, suggesting that the
conformation of genomic RNA is important for the
packaging process [9,10]. Furthermore, mutation ana-
lyses indicate that all of these structures are important
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for viral genomic RNA packaging [9-11]. The four SLs
in the 5′ untranslated region (UTR) of the viral genome
act as the primary recognition sites for the nucleocapsid
(NC) domain of the Gag polyprotein [7,11-16]. The NC
has been shown to mediate the selection of unspliced
viral genomic RNA for packaging through the interac-
tion of its zinc finger motifs and SL3 of the viral RNA
[17,18]. However, viral RNA lacking SL3 is still encapsu-
lated into the virion [11,19], as SL1, SL2 and SL4 also
interact with the NC domain during packaging [7,16].
Within the virion, HIV-1 genomic RNA exists as a
dimer held together by a noncovalent linkage at the 5′
end [1,4]. The dimerization process is thought to occur
in the cytoplasm, and the HIV-1 genomic RNA mole-
cules are then packaged as a dimer [3,5,20]. Though the
5′ transactivation response stem-loop may play a role in
HIV-1 RNA dimerization [21], the viral element that
directs the dimerization process is a 6-nt palindromic
sequence called the dimerization initiation signal (DIS),
which is located at the loop of SL1 in the 5′ UTR
[3,4,9,22-26]. The DIS of two RNA molecules first form
base pairs to initiate the dimerization process and form
a kissing loop complex [23,24,27-29]. The NC then pro-
motes the conversion of the kissing loop complex to a
more stable extended dimer [30,31]. Recent studies have
shown that base-pairing of the DIS of two RNA mole-
cules is a major determinant in the selection of the
copackaged RNA partners, and the identity of the DIS
plays an important role in the copackaging of RNAs
from different HIV-1 strains [3,25,32].
Given the critical role of SL1 in viral RNA dimeriza-
tion and packaging, it is not surprising that deletion of
SL1 from a replication competent HIV-1 molecular
clone renders the virus non-infectious in human T cell
lines [11,33-37]. However, SL1 deletion mutants have
been shown to replicate in human PBMCs, and a pri-
mary HIV-1 isolate with a defect in RNA dimerization
has been identified in a patient [35,36,38]. The underly-
ing mechanism of this cell type-dependent restriction is
unclear. Because human PBMCs are more heteroge-
neous in nature than T cell lines, one possibility is that
a subset of the PBMC population is able to support the
replication of SL1 deletion mutants. It remains to be
discovered whether such a subset of cells exists or
whether the presence or absence of a cellular factor is
responsible for overcoming the SL1 mutant replication
restriction.
Several restrictions on the replication of SL1 deletion
mutant in T cell lines have been identified, including
viral RNA dimerization and packaging in producer cells
and reverse transcription (RT) of the viral RNA in
infected cells [10,11,33-37,39,40]. Long-term culture of
SL1 mutants generates revertants that retain the SL1
deletion but possess compensatory mutations in Gag
[33,34,41]. SL1 deletion mutants generally package less
full-length HIV-1 genomic RNA and more spliced viral
RNA into the virion, whereas spliced RNA is effectively
excluded from packaging in the revertants. Thus, these
compensatory mutations may partially rescue SL1 dele-
tion mutant infectivity by enhancing the packaging spe-
cificity of Gag. However, the molecular mechanism
underlying the rescue of viral RNA packaging in SL1
deletion mutant revertants has not been defined. More-
over, the effects of SL1 deletion on viral RNA splicing
and cellular RNA packaging are unclear.
Here we report two independent adaptations of HIV-1
that partially restored infectivity in SL1 deletion mutants
in a restrictive cell line in as little as 11 days. The rever-
tants retained the SL1 deletion but harbored compensa-
tory mutations in Gag. SL1 deletion mutants carrying
these compensatory mutations were effective in exclud-
ing spliced viral RNA from packaging. We show that
reduced association between the mutated Gag and
spliced viral RNA plays a major role in the exclusion of
spliced HIV-1 RNAs in the revertants.
Results and Discussion
Replication of HIV-1 SL1 deletion mutant in PM-1 cells
Previous studies have shown that HIV-1 SL1 deletion
mutants do not replicate in human T cell lines and
that compensatory mutations that partially rescue the
replication defect arise after several passages in culture
[33,34,41]. In this study, a SL1 deletion mutant
demonstrated delayed replication in a human T cell
line. The SL1 deletion mutant, NLΔSL1, was derived
from a replication-competent NL4-3 molecular clone
with the 43-nt SL1 deleted (nt position 691 to 733,
NL4-3 proviral DNA). In PM-1 cells infected with
NLΔSL1, syncytia were observed 14 days postinfection
(p.i.) in one culture and 22 days p.i. in another,
whereas NL4-3 infected cells showed syncytia by
7 days p.i. (data not shown). Virus production in the
infected PM-1 cells was detected in the culture super-
natant 3-4 days before cytopathogenicity was observed
using TZM-bl indicator cells (Figure 1A) and p24
ELISA (Additional file 1: Figure S1).
The two distinct growth kinetics of NLΔSL1 in PM-1
cells, shown in Figure 1A, suggest that variants of
NLΔSL1 with enhanced infectivity may have emerged in
the infected cultures on day 14 p.i. and day 22 p.i. To
confirm the presence of new variants with enhanced
infectivity, equal amounts of p24-normalized NL4-3,
NLΔSL1 and viruses from the infected PM-1 cells on
day 14 p.i. (NLΔSL1-D14) and on day 22 p.i. (NLΔSL1-
D22) were used to infect fresh PM-1 cells, and virus
production was monitored. NLΔSL1-D14 and NLΔSL1-
D22 indeed replicated with higher efficiency than the
original NLΔSL1 (Figure 1B).
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Identification of compensatory mutation in the SL1
deletion revertants
To identify the mutations responsible for the increased
infectivity of NLΔSL1 and to rule out the possibility that
NLΔSL1 had reverted the SL1 deletion, we isolated viral
RNA from the culture supernatants, and amplified and
sequenced the near full-length genome of the virus.
Sequences derived from NLΔSL1-D14 and NLΔSL1-D22
showed that both variants still harbored the SL1 dele-
tion found in NLΔSL1 (data not shown). A G913A sub-
stitution (NL4-3 numbering) was found in the matrix
(MA) of NLΔSL1-D22, leading to an E42K amino acid
change in the protein, and a C1907T substitution was
found in the SP1 of NLΔSL1-D14, corresponding to a
P10L substitution. Neither mutation had been associated
with enhanced infectivity of HIV-1 prior to this study,
nor did we identify additional mutations in other parts
of the mutant genomes. A survey of 9675 subtype B
MA protein sequences retrieved from the Los Alamos
HIV Sequence Database showed that almost all
sequences harbor glutamic acid at position 42, whereas
lysine was detected in only 10 sequences. Leucine was
not present at position 10 in any of 4454 subtype B SP1
peptide sequences retrieved from the sequence database
(sequence alignments available upon request). These
results suggest that these two compensatory mutations
are uncommon in naturally occurring HIV-1 strains.
Furthermore, these data indicate that more than one
mutational pathway can compensate for the loss of SL1
secondary RNA structure.
Compensatory mutations in gag rescue the replication
defect of the SL1 deletion mutant
To verify the contribution of mutations G913A and
C1907T to the enhanced infectivity of the SL1 mutant,
we performed site-directed mutagenesis of NLΔSL1 to
generate NLΔSL1-913, NLΔSL1-1907 and NLΔSL1-913/
1907 strains. The mutant vectors were identical to the
NLΔSL1 sequence, except that NLΔSL1-913 contained a
G913A substitution in the MA gene, NLΔSL1-1907 had
a C1907T mutation in the SP1 region and NLΔSL1-913/
1907 harbored both mutations. Equal amounts of p24-
normalized NL4-3, NLΔSL1, NLΔSL1-913, NLΔSL1-
1907 or NLΔSL1-913/1907 were used to infect PM-1
cells, and growth kinetics were measured. SL1 deletion
revertants having mutations in MA, SP1 or both demon-
strated intermediate replication efficiencies between
NL4-3 and NLΔSL1 (Figure 2). Combining the two
mutations did not further enhance replication, as the
NLΔSL1-913/1907 showed similar replication efficiency
to NLΔSL1-913 and NLΔSL1-1907. This result indicates
that mutation in either MA or SP1 is sufficient to par-
tially restore the replication of the SL1 deletion mutant.
NL4-3 carrying the G913A (NL-913) or C1907T (NL-
1907) mutation or both (NL-913/1907) was included for
comparison. None of these mutations affected the repli-
cation of the NL4-3 virus (Figure 2). Taken together,
these results confirm that point mutations in MA or
SP1 were responsible for the enhanced infectivity of the
NLΔSL1 revertants.
Compensatory mutations in gag increase the production
of infectious SL1 deletion mutant virus
HIV-2 carrying a mutated Ψ/SL1 reportedly has defec-
tive packaging of viral RNA and produces fewer mature
particles, thus reducing the overall infectivity of the
virus [42,43]. We postulated that SL1 deletion mutants
could have a similar defect that affects the production
of infectious virions. To evaluate virus production of the
SL1 deletion mutants, we measured virion-associated
p24 in the viral stocks after centrifugation through a
sucrose cushion. Virus production in the deletion
Figure 1 Replication kinetics of NL4-3, NLΔSL1, and revertants.
(A) Changes in the infectivity of NLΔSL1 were observed. PM-1 cells
were infected with p24-normalized NL4-3 or NLΔSL1. Virus
production was measured in TZM-bl cells using culture supernatant
from the infected PM-1 at different times. (B) NLΔSL1 revertants
were replication competent in PM-1 cells. Culture supernatants from
day 14 p.i. with NLΔSL1#1 (NLΔSL1-D14) and day 22 p.i. with
NLΔSL#2 (NLΔSL1-D22) were normalized to p24 and used to infect
fresh PM-1 cells, and virus production was detected as described
previously.
Figure 2 Mutations in Gag are responsible for the changes in
infectivity of NLΔSL1. NL4-3 and NLΔSL1 carrying the G913A or
C1907T mutations were normalized with p24 amount and used to
infect PM-1 cells. Virus production was measured in TZM-bl cells
using culture supernatant harvested from the infected cells at
different times.
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mutants was not affected by the absence of SL1 or by
point mutations in MA or SP1 (Figure 3A). Western
blot analysis of pelleted virion from cells transfected
with the mutant constructs showed that the expression
and processing of HIV-1 proteins were similar to those
of the wild-type virus with a slight increase in unpro-
cessed p41 (MA-capsid) in the SL1 deletion mutant
(Figure 3B). However, when the same virion samples
were analyzed in Western blot with p17 monoclonal
antibody, we did not observe a difference in the level of
MA (data not shown). We then determined the infec-
tious titer of the virus, normalized against the amount
of p24, to quantify the production of infectious virus by
the mutants. NLΔSL1 produced 20-fold fewer infectious
viral particles than the wild-type NL4-3 (Figure 3C),
whereas NLΔSL1-913 and NLΔSL1-1907 produced only
about 1.7-fold fewer infectious viruses compared to the
wild type. It is likely that changes in the Gag protein
sequence were responsible for the increased infectious
virus production, but changes in the RNA sequence may
also have played a role. We therefore investigated if the
compensatory mutations in gag affected the infectivity
of the deletion mutants at the RNA level.
Compensatory mutations do not affect the dimerization
or splicing of HIV-1 RNA
The SL1 of HIV-1 is responsible for directing viral RNA
dimerization and is located very close to the major splice
donor of the SL2 in the 5′ leader sequence. We deter-
mined whether dimerization and splicing of the RNAs
were affected by the deletion in SL1. Because the SL1
contains a major signal for viral RNA dimerization, we
expected to find decreased levels of RNA dimer in the
deletion mutant. Indeed, the NLΔSL1 had 53% dimerized
RNA, compared with 94% in the wild type (Figure 4A
and 4B). We then asked whether the compensatory
mutations could rescue the RNA dimerization defect,
and found that neither of the substitutions had a signifi-
cant effect on the amount of dimeric RNA (47-45%).
We next investigated the effects of the SL1 deletion
and compensatory mutations on HIV-1 RNA splicing.
We specifically reverse-transcribed and amplified the
4-kb singly spliced viral RNA using primers targeting
the U5 and vpu of the HIV-1 genome and analyzed the
products by agarose gel electrophoresis. The PCR pro-
ducts from the wild type were as expected [44], and the
identities of the bands were verified by sequencing as
vpr, tat and vpu RNAs (Figure 4C). The SL1 deletion
mutant and the revertants yielded similar products,
though of smaller sizes due to the 43-nt SL1 deletion.
Sequence analysis showed that the SL1 mutant and
revertants used the same splicing sites as the wild type.
Moreover, we did not see a marked change in RNA sta-
bility in either the wild type or the SL1 deletion mutants
Figure 3 Analyses of the production and infectivity of viral
particles. (A) Similar virus production from NL4-3 and deletion
mutants. Culture supernatants of 293T cells transfected with the
corresponding vectors were centrifuged through a 20% sucrose
cushion. The amount of p24 in the virus pellets was determined
and compared to the amount of p24 in the NL4-3 virus pellet,
which was set at 100%. Means and SD of three independent
experiments are shown. (B) NL4-3 and deletion mutants had similar
protein expression and processing. Western blot analysis of HIV-1
virions with p24 or gp120 antiserum. The corresponding sizes of the
HIV-1 proteins are shown to the right. (C) Infectious virus
production varied among different mutants. Viruses harvested from
the culture supernatant of 293T cells transfected with the
corresponding vector were titrated for infectivity using the limiting
dilution culture method in PM-1 cells. The TCID50 was calculated by
the Reed and Muench method. The same aliquot of virus was
quantified with p24 ELISA and used to normalize the titer of the
virus stock. Means and SD of three independent experiments are
shown. *, indicates p < 10-3 and significant deviation from the wild-
type infectious virus titer as determined by Student’s t test.
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with the compensatory mutations (Table 1). Notably, the
SL2 remains intact in the absence of SL1, confirming
that RNA splicing was not affected in the NLΔSL1
mutant (Additional file 2: Figure S2). However, one has
to caution that analyzing HIV-1 RNA monomer in solu-
tion may not completely reveal the elusive native struc-
ture and stability of dimeric viral RNA in the cell.
Nonetheless, these data indicate that the two compensa-
tory mutations in gag do not rescue infectivity in the
SL1 deletion mutant by altering RNA dimerization or
splicing.
Compensatory mutations in Gag partially rescue the SL1
deletion mutant RNA packaging defect
SL1 is not located within a promoter and does not code
for any viral protein; thus SL1 deletion did not affect
the expression or processing of HIV-1 proteins (Figure
3B) [11,35,37]. Based on previous studies, we predicted
that the SL1 deletion reduces packaging efficiency
[10,11,33-35,37,40,45] and packaging selectivity of viral
RNAs [11,14,34,40,45]. To explore this possibility, quan-
titative PCR (qPCR) using primer/probe sets specific for
HIV-1 genomic RNA, env mRNA, or rev mRNA were
used to measure the amounts of different RNA species
packaged into the virion. The amount of HIV-1 genomic
RNA, env mRNA or rev mRNA in the virion is an indi-
cation of the packaging efficiency of full-length
unspliced, singly spliced, and fully spliced RNA,
respectively.
We found that the genomic RNA of NLΔSL1 was
packaged about half as efficiently as that of NL4-3 (Fig-
ure 5A). This result supports the notion that SL1 plays
a role in binding Gag during packaging [7,11,46]. In
contrast, 3- to 4-fold more NLΔSL1 env and rev mRNA
was packaged into the virion compared to the wild type
(Figure 5B) consistent with previous studies showing
that SL1 deletion led to an increased packaging of
spliced viral RNAs into the virion [11,14,34,40,45]. The
deletion in SL1 increased the amount of spliced mRNA
over the amount of genomic RNA by 7- to 9-fold (Fig-
ure 5C). The abnormal amount of spliced and unspliced
Figure 4 Characterization of the dimerization state and
splicing of viral RNA. (A) Dimerization analysis of virion RNA. Virion
RNAs of different proviral constructs were separated on a native
agarose gel and characterized by Northern analysis. Dimer and
monomer are indicated on the right side of the blot. Results are
representative of two sets of experiments. (B) Compensatory
mutations in gag did not affect RNA dimerization. Amounts of
dimeric and monomeric RNA were quantified by densitometry, and
the percentages of dimers for each construct present in the virion
calculated. Means and SD of two independent experiments are
shown. (C) Deletion of SL1 did not affect the splicing of HIV-1 RNAs.
293T cells were transfected with the HIV-1 constructs. Total RNA
was isolated 48 hrs post-transfection and reverse-transcribed. The 4-
kb singly spliced HIV-1 RNAs were amplified from cDNA and
separated on an agarose gel. The SL1 deletion resulted in a
population of smaller mRNAs than those observed for the wild-type
HIV-1. Sequence analysis verified the identity of the products and
showed that the deletion mutants had the same splicing patterns
as the wild-type virus.
Table 1 Stability of HIV-1 genomic RNA as predicted in
Mfold







a Genomic RNA nt 456 to 2080 of NL4-3, NL-913 and NL-1907, and nt 456 to
2037 of NLΔSL1, NLΔSL1-913 and NLΔSL1-1907 were used for folding
predictions.
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NLΔSL1 RNA in the virions was not due to differences
in expression, as the RNAs of NL4-3 and NLΔSL1
showed similar expression levels in the producer cells
(Figure 5D).
It is possible that the packaging of excess spliced viral
mRNA in NLΔSL1 mutants is associated with the
reduced production of infectious virions, thereby redu-
cing the overall infectivity of the virus. In support of this
hypothesis, we found that the compensatory mutations
did not rescue the defect in packaging HIV-1 genomic
RNA (Figure 5A), but rather that both the NLΔSL1-913
and NLΔSL1-1907 revertants efficiently excluded spliced
viral mRNA from packaging (Figure 5B). The SL1 dele-
tion mutant carrying the mutation in MA, NLΔSL1-913,
had about 1.5-fold less env and rev mRNA in the virion
compared to the wild type, whereas the SP1 mutant,
NLΔSL1-1907, had about a 4-fold reduction in viral
mRNA species in the virion. In addition, both mutations
restored the relative amount of spliced mRNA and
unspliced genomic RNA in the virion similar to that of
the wild type (Figure 5C). These results are consistent
with a previous study demonstrating that HIV-1 of the
BH10 strain acquires mutations in the MA (V35I) and
SP1 (T12I) domains to compensate for the SL1 deletion
Figure 5 Quantification of HIV-1 RNA content in the virion. (A) Efficiency of HIV-1 genomic RNA packaging. RNA was isolated from
equivalent amounts of p24 from NL4-3, NLΔSL1, NLΔSL1-913 and NLΔSL1-1907, reverse-transcribed and measured by qPCR with a primer/probe
set specific to the HIV-1 unspliced genomic RNA. The amount of NL4-3 genomic RNA was set at 100%. Copy numbers ranged from 2.0 × 106 to
2.9 × 106 in four independent experiments. *, indicates p < 10-4 and significant deviation from the wild-type copy number as determined by
Student’s t test. (B) Efficiency of spliced HIV-1 RNA packaging. cDNA was subjected to qPCR targeting the env mRNA or rev mRNA sequence as
described above. The amount of NL4-3 spliced mRNA was set at 100%. Copy numbers of env mRNA ranged from 24,042 to 28,865, and rev
mRNA from 8,387 to 14,335 in four independent experiments. *, indicates significant deviation from the wild-type copy number as determined
by Student’s t test; p < 10-4, except for NLΔSL1-913, p < 10-3. (C) Relative amounts of HIV-1 genomic RNA and mRNA in the virion. The copy
numbers of HIV-1 genomic RNA and env and rev mRNA were used to calculate the relative amount of mRNA in the virion [(mRNA copy/
genomic RNA copy) × 100] and normalized to genomic RNA level. (D) Determination of viral RNA expression in producer cells. Total RNA was
isolated from 293T cells transfected with the corresponding vectors and reverse transcribed. The cDNA was quantified by qPCR with primer/
probe sets specific for the HIV-1 genomic RNA, env mRNA and rev mRNA sequences. The copy number in each sample was adjusted for input
by the level of PBGD mRNA and for transfection efficiency by GFP expression from a co-transfected reporter construct. The amount of NL4-3
RNA was set at 100%.
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[34]. In that study, the lone SP1 mutation was sufficient
to restore the packaging efficiency and specificity of the
Gag, however, SL1 deletion revertant carrying only the
MA mutation was not characterized. Moreover, our
study supports the notion that the SP1 domain may have
a role in HIV-1 RNA packaging [47].
Previous studies have shown that SL1 deletion impairs
plus-strand HIV-1 DNA transfer in RT [37,39]. In addi-
tion, recombination is restricted in a 2-kb region imme-
diately downstream of SL1 mutations [48] affecting the
efficiency of RT and the synthesis of full-length HIV-1
DNA [49]. However, it is unlikely that the mutations in
MA and SP1 restore infectivity by rescuing the defects
in RT. Indeed, NLΔSL1-913 and NLΔSL1-1907 are still
defective in plus-strand DNA transfer (Ristic and Chin,
unpublished data) indicating that the compensatory
mutations do not have a role in RT. On the other hand,
because HIV-1 spliced mRNA does not contain the gag
sequence [44], the two compensatory mutations are
unlikely to affect the packaging efficiency of spliced
mRNA at the RNA level. Therefore, the mutations in
MA and SP1 likely enable the Gag polyprotein to effec-
tively exclude spliced NLΔSL1 mRNA during packaging.
The compensatory mutations led to changes in part of
the predicted secondary structures of the HIV-1 geno-
mic RNA, but the SLs remained unchanged (Additional
file 2: Figure S2). However, despite the changes in pre-
dicted secondary structure, the packaging efficiency of
HIV-1 genomic RNA was not altered, suggesting that
the SLs are the dominating cis-acting element in the
packaging process. Further experiments studying viral
RNA packaging efficiency by supplying the mutant Gag
in trans are needed to confirm this observation. In addi-
tion, fluorescence microscopy analysis on the mutant
Gag within the cell may be necessary to exclude the
possibility that the mutations have changed the subcel-
lular localization or trafficking of Gag, resulting in a
change in RNA binding preference.
Reduction of HIV-1 genomic RNA is accompanied by an
increase in packaging of cellular RNA into the SL1
deletion mutant virion
HIV-1 packages cellular RNA into the virion [40,50-54].
A previous study has shown that in the absence of packa-
ging signal, murine leukemia virus and HIV-1 package
less genomic RNA and more cellular mRNA, but main-
tain roughly the same amount of RNA as the wild-type
virion [50]. In this study, the absence of SL1 led to a
reduction of HIV-1 genomic RNA in the virion (Figure
5A). It is possible that the genomic RNA in the SL1 dele-
tion virion was replaced by host RNA and that the virion
maintained an RNA level similar to that of wild type. To
characterize the cellular RNA packaged into the wild-
type and SL1 deletion mutant virions, we used qPCR to
measure the packaging efficiency of Y1, Y3, and signal
recognition particle (SRP) RNAs, which are the most
abundant cellular RNAs in the HIV-1 virion [52,53].
We found that in the absence of SL1, Gag packaged
about 1.5- to 1.7-fold more Y1, Y3 and SRP RNA into
the virion compared to wild type (Figure 6). The rever-
tant Gag did not affect the packaging efficiency of the
cellular RNA, suggesting that the increased level of cel-
lular RNA did not affect the infectivity of the virus.
Thus, it appears that cellular RNAs were packaged
into the virion to fill in the “void” caused by the reduc-
tion of genomic RNA in the SL1 deletion mutants.
This is consistent with previous studies showing that
reduced packaging of genomic RNA is accompanied by
increased incorporation of cellular RNA in the virion
[40,50]. We compared the RNA copy numbers in the
wild-type and NLΔSL1 virions and found that
increased copies of env and rev mRNA, Y1, Y3, and
SRP RNA in the NLΔSL1 virion accounted for
approximately 67% of the reduction in HIV-1 genomic
RNA in the virion. These data suggest that in addition
to the viral mRNAs and cellular RNAs reported here,
Gag also packages other RNA species to replace the
decreased amount of HIV-1 genomic RNA in the
NLΔSL1 virion. This also hold true for the revertant
virions which likely package other RNA species to
replace the decreased amount of HIV-1 genomic and
spliced RNA.
Figure 6 Characterization of the cellular RNA in the wild-type
and SL1 deletion mutant virions. The same cDNA preparations
used to measure HIV-1 RNA content in the virion in Figure 5 were
subjected to qPCR characterization targeting cellular Y1, Y3 and SRP
RNA. The amount of cellular RNA in the NL4-3 virion was set at
100%. Copy numbers for Y1, Y3 and SRP RNA were 275-362, 1,710-
2,006 and 1.1 × 106-1.3 × 106, respectively, as determined in four
independent experiments.
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The associations between Gag and HIV-1 RNA correlate
with the preference of Gag in packaging different species
of RNA
The primary recognition sites for NC are the four SLs in
the 5′ UTR of the HIV-1 genome [7,11-16]. Biochemical
analysis has indicated that short RNAs possessing HIV-1
SL2 or SL3 have the highest affinity for NC, whereas those
with SL1 or SL4 have lower affinity for NC [46]. Our data
indicate that in the absence of SL1, Gag packaged less
HIV-1 genomic RNA, but incorporated significantly more
spliced HIV-1 mRNA into the virions confirming and
extending previous results on the packaging of spliced
viral RNA in SL1 mutants [11,14,34,40,45]. Despite the
presence of a packaging signal in the NLΔSL1 genomic
RNA, the association between the mutant genomic RNA
and Gag may have been reduced, leading to the reduction
in packaging efficiency. It is also possible that the deletion
of SL1 disrupted an essential secondary RNA structure
within the 5′ leader on the spliced viral mRNA that is
important for Gag to actively select and exclude spliced
viral mRNA from packaging. In the Mfold analysis, dele-
tion of SL1 changes the structures within the 5′ leader of
env and rev mRNA, but the physiological relevance is not
clear (data not shown). We therefore propose that the
compensatory mutations in MA or SP1 play a role in mak-
ing Gag more effective in preventing spliced NLΔSL1
mRNA from being packaged. Based on this prediction, we
hypothesized that the compensatory mutations in MA or
SP1 reduce the association between Gag and spliced viral
mRNA, thereby reducing the likelihood of spliced viral
mRNA being packaged into the virion. To test this
hypothesis, we quantified Gag and HIV-1 RNA association
by immunoprecipitation, followed by qPCR as previously
described with modifications [55].
In these experiments, we observed different associa-
tions between Gag and the RNAs of NL4-3, the SL1
deletion mutant, and the revertants, although these vec-
tors had similar RNA expression in the producer cells
(Figure 4). Specifically, 3-fold less NLΔSL1 genomic
RNA was immunoprecipitated by Gag (Figure 7A). Gag
carrying mutations in MA or SP1 did not show a signifi-
cantly altered binding preference and associated with 2-
to 3-fold less HIV-1 genomic RNA compared to NL4-3
(Figure 7A). These results suggest that the drop in
packaging efficiency of NLΔSL1 genomic RNA is caused
by a reduced association of Gag with the ΔSL1 RNA.
We then examined the association between Gag and
spliced HIV-1 mRNA. Compared to the wild type, we
found that Gag showed an enhanced association with
NLΔSL1 spliced mRNA, immunoprecipitating about 4-
fold more singly spliced and fully spliced RNA (Figure 7B).
This is consistent with the viral RNA packaging result
(Figure 5B). Importantly, Gag carrying mutations in MA
or SP1 showed significantly reduced association with
spliced HIV-1 mRNA compared to the wild type; 3- to
5-fold less HIV-1 mRNA was associated with the revertant
Figure 7 Characterization of the association between Gag and HIV-1 RNA. (A) Measurement of the association between Gag and HIV-1
genomic RNA. HIV-1 genomic RNA immunoprecipitated with the Gag was characterized by qPCR using a primer/probe set targeting the
unspliced RNA transcript. (B) Measurement of the association between Gag and spliced HIV-1 mRNA. The same cDNA preparation described
above was subjected to qPCR using a primer/probe set specific for env mRNA and rev mRNA sequences. The copy number in each sample was
adjusted for input by the cell number and for transfection efficiency by GFP expression from a co-transfected reporter construct. The amount of
NL4-3 RNA was set at 100%. Means and SD of three independent experiments are shown. *, indicates p < 10-4 and significant deviation from the
wild-type copy number as determined by Student’s t test.
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Gag compared to that of NL4-3 (Figure 7B). Thus, the
association between Gag and viral RNA could directly
affect the packaging efficiency of different viral RNA spe-
cies in the SL1 deletion mutant and its revertants. It will
be interesting to find out if the SP1 (T12I) revertant of the
SL1-deleted BH10 also use similar mechanism to exclude
spliced RNA from encapsidation and restore infectivity
[34]. In vitro binding assay can be used to confirm the
above association between mutant Gag and HIV-1 RNA,
but one caveat is that such experiment may not reflect the
Gag-RNA association in the physiological condition of a
cell. Taken together, these data indicate that HIV-1 can
adapt to a severe genetic defect in SL1 through mutations
in MA or SP1 that reduce the association of Gag to spliced
ΔSL1 HIV-1 RNA, thus effectively preventing these RNAs
from being packaged and subsequently increasing the pro-
duction of infectious virions.
Conclusion
We demonstrated new pathways for HIV-1 to compen-
sate for a deletion of SL1. A G913A (E42K) mutation in
MA and a C1907T (P10L) mutation in SP1 were
responsible for the enhanced infectivity of NLΔSL1 in
PM-1 cells through partially restoring the packaging
specificity of viral RNA. These compensatory mutations
may enable Gag to exclude spliced viral RNA from
packaging and interfere with the production of infec-
tious virus in SL1 deletion mutants. Prior to this study,
no mutations at either of these amino acid positions in
Gag had been associated with restoring the infectivity of
a mutant. We also present evidence that both mutations
affect the Gag-HIV-1 RNA association in a cell-based
system. This study provides new insights into the func-
tions of the N-terminal MA domain and SP1 and sug-
gests that both regions may have a role in interacting
with different spliced viral RNA transcripts.
Methods
Plasmid construction, cell culture and virus
The pNL4-3 molecular clone was obtained from the NIH
AIDS Reagent Program [56] and was used for the con-
struction of mutant vectors in this study. A 43-nt region
encompassing the SL1 of pNL4-3 (nt position 691 to 733
of proviral DNA) was deleted by site directed mutagen-
esis to generate pNLΔSL1. The G913A substitution was
made to the pNL4-3 and the pNLΔSL1 vectors to gener-
ate pNL-913 and pNLΔSL1-913, respectively, by the
QuikChange II XL Site-Directed Mutagenesis Kit (Agi-
lent). Using similar approach, the C1907T substitution
was made to pNL4-3 and pNLΔSL1 to generate pNL-
1907 and pNLΔSL1-1907, respectively.
The HIV indicator cell line TZM-bl and human T cell
line PM-1 were obtained from the NIH AIDS Reagent
Program [57,58]. Human embryonic kidney cell line
293T and TZM-bl cells were cultured in Dulbecco’s
modified Eagle’s medium. PM-1 cells were cultured in
Roswell Park Memorial Institute-1640 medium. Medium
was supplemented with 10% fetal calf serum, penicillin
(50 U/ml), and streptomycin (50 mg/ml).
Viruses were generated from 293T cells by transfec-
tion using the standard calcium phosphate method.
Forty-eight hours after transfection, the culture superna-
tant was harvested and passed through a 0.45-μm-pore
size filter to remove cellular debris, and centrifuged
through a 20% sucrose cushion. The virus pellet was
resuspended in PBS and quantified by p24 ELISA
(Advanced BioScience Laboratories). The TCID50 of the
virus was determined by the Reed and Muench method.
Infection of PM-1 cells and measurement of viral
replication
A total of 5 × 105 cells were inoculated with 10 ng of
p24-normalized virus for 4 hours. Unbound viruses
were removed by washing with PBS, and the infected
cells were cultured in 6-well plates. Cells were split 1:2
every 7 days. Culture supernatants were collected at dif-
ferent times for detection of infectious virus by TZM-bl
cells or measurement of p24 by ELISA.
Sequencing of the HIV-1 genome
Viral RNA was isolated from the infected culture superna-
tants using the QIAamp Viral RNA Mini Kit (Qiagen) and
converted to cDNA with random hexamers using Super-
Script III reverse transcriptase (Invitrogen). The cDNA was
amplified using the FastStart High Fidelity PCR System
(Roche) in four overlapping fragments covering the near full-
length genome of NL4-3. The PCR products were sequenced
with overlapping primers, and the resulting sequence contigs
were assembled with the Staden Package (PCR and sequen-
cing primer sequences are available upon request) [59].
Every nucleotide was identified by at least two sequence con-
tigs to ensure the accuracy of the DNA sequence.
Western blot analysis of viral proteins
HIV-1 virion equivalent to 100 ng of p24 was pelleted by
centrifugation and resuspended in sample buffer contain-
ing 5 mM b-mercaptoethanol. Samples were separated by
SDS-PAGE and transferred to PVDF membrane. Blot was
probed first with antiserum to HIV-1 p24 or gp120
(obtained from Dr. Michael Phelan through the NIH
AIDS Reagent Program) [60] and then with horseradish
peroxidase-conjugated secondary antibody (Thermo
Scientific). The blot was developed by an enhanced che-
miluminescence detection reagent (GE Healthcare).
Splice site analysis
Total RNA was isolated from 2 × 106 293T cells transfected
with different HIV-1 constructs using TRIzol LS Reagent
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(Invitrogen). The RNA was converted to cDNA and ampli-
fied in a standard PCR using forward primer specific for
the NL4-3 U5 (nt 551-570) and reverse primer specific for
the vpu (nt 6220-6199). The PCR products were analyzed
in a 2% agarose gel, gel purified and cloned into the pCR4-
TOPO TA cloning vector (Invitrogen) for sequencing.
Northern blot analysis of virion RNA dimers
Virion equivalent to 200 ng of p24 was pelleted, and the
viral RNA was extracted using TRIzol LS Reagent
(Invitrogen) and treated with DNase I. The RNA was
separated on a nondenaturing agarose gel in 1× TBE
buffer. After electrophoresis, the gel was incubated in
6% formaldehyde at 65°C for 30 min, and the RNA was
transferred to a nylon membrane. RNA was cross-linked
to the membrane and detected by a 235-nt RNA probe
synthesized using the DIG Northern Starter Kit (Roche),
which corresponds to the R-PBS region of HIV-1 (456
to 690, NL4-3 numbering). Hybridization and detection
of the DIG-labeled RNA probe followed the manufac-
turer’s protocol, which utilized a chemiluminescence
detection reagent. RNA on the membrane was quanti-
fied by densitometry using ImageJ software.
RNA secondary structure prediction
RNA secondary structure prediction was performed
using Mfold v3.2 [61,62], hosted by the Rensselaer Poly-
technic Institute http://mfold.bioinfo.rpi.edu. Folding
conditions were 37°C and 1 M NaCl. Sequences com-
prising nt 456 to 2080 of the NL4-3, NL-913 and NL-
1907 genomic RNAs and nt 456 to 2037 of the
NLΔSL1, NLΔSL1-913 and NLΔSL1-1907 genomic
RNAs were used for the folding predictions.
Quantitative PCR measurement of RNA
Equivalent amounts of p24 from NL4-3, NLΔSL1,
NLΔSL1-913 and NLΔSL1-1907 were treated with
DNase I and digested with proteinase K. Viral RNA was
isolated with 6 M guanidinium isothiocyanate in the pre-
sence of GlycoBlue Coprecipitant (Ambion) and precipi-
tated with isopropanol. The resulting viral RNA was
converted to cDNA with random hexamers using Super-
Script III reverse transcriptase (Invitrogen) and treated
with Dpn I. The cDNA was then subjected to qPCR
using primer/probe sets specific for the HIV-1 genomic
RNA, env mRNA or rev mRNA using TaqMan Gene
Expression Master Mix (Applied Biosystems) according
to the manufacturer’s protocol. The same cDNA prepara-
tions were also subjected to qPCR using primers specific
to the cellular RNA, Y1, Y3 and SRP RNA and the Fast
SYBR Green Master Mix (Applied Biosystems). All pri-
mer and probe sequences are available upon request.
For the analysis of viral RNA expression in the producer
cells, 293T cells transfected with the corresponding vectors
were harvested and washed with PBS. Total RNA was iso-
lated from 2 × 106 cells using TRIzol LS Reagent. The iso-
lated RNA was treated with DNase I before conversion to
cDNA using random hexamers. The resulting cDNA was
further treated with Dpn I and quantified by qPCR with
primer/probe sets specific for the HIV-1 genomic RNA,
env mRNA and rev mRNA sequences as described pre-
viously. The transfection efficiency was determined by
measuring the percentage of GFP+ expression from a co-
transfected reporter construct. The copy number in each
sample was normalized to the level of PBGD mRNA.
Characterization of Gag and HIV-1 RNA association in vivo
A previously described protocol with modifications was
used [55]. 293T cells transfected with NL4-3, NLΔSL1,
NLΔSL1-913 or NLΔSL1-1907 were trypsinized and
washed three times with PBS to wash away virion on the
cell surface. The cells were suspended in PBS containing
1% formaldehyde and incubated for 10 min at room tem-
perature to cross-link proteins and RNAs in the cell. The
cross-liking reaction was quenched with 125 mM glycine
for 5 min at room temperature and washed three times
with ice cold PBS. Cells were lysed in RIPA buffer (Pierce)
and sonicated in the presence of complete protease inhibi-
tor cocktail (Roche) and RNaseOUT (Invitrogen). The cell
lysate was clarified by centrifugation and the Gag-RNA
cross-linked complex was immunoprecipitated with anti-
p24 monoclonal antibody (clone 24-4) (Santa Cruz Bio-
technology) bound to Dynabeads Protein G (Invitrogen).
The immunoprecipitated complex was washed according
to the manufacturer’s protocol with the addition of 1 M
urea. The sample was then heated to 70°C to reverse the
cross-linkages between RNA and Gag. The released RNA
was precipitated with isopropanol, digested with DNase I
and then subjected to reverse transcription. qPCR was
used to measure the amount of HIV-1 genomic RNA, env
mRNA and rev mRNA as described previously. The trans-
fection efficiency was determined by measuring the per-
centage of GFP+ expression from a co-transfected reporter
construct. The number of cell in the input material was
standardized using TruCount Absolute-Count tube (BD
Biosciences) and flow cytometry.
Additional material
Additional file 1: Supplemental Figure S1. Replication of NL4-3 and
NLΔSL1 in PM-1 cells as determined by p24 ELISA. PM-1 cells were
infected with p24-normalized NL4-3 or NLΔSL1. Culture supernatants
from the infected PM-1 were collected at different times, and p24 levels
were measured by ELISA.
Additional file 2: Supplemental Figure S2. Predicted secondary
structures of NL4-3 and SL1 deletion mutants. Genomic RNA of (A) NL4-
3, (B) NL-913 and (C) NL-1907 (nt 456 to 2080) and (D) NLΔSL1, (E)
NLΔSL1-913 and (F) NLΔSL1-1907 (nt 456 to 2037) were subjected to
Mfold analysis. The SL1 and SL2 and the positions of the MA (913) and
SP1 (1907) substitutions are labeled.
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